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Abstract 
Review on t(1;8)(p11-13;q24), with data on clinics, 
and the genes involved. 
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Clinics and pathology 
Disease 
Multiple myeloma (MM) mainly 
Epidemiology 
Multiple myeloma in 14 cases, found mainly in 
male patients (12 males and 1 female, 1 
unknown) (Sawyer et al., 1998; Marzin et al., 
2006; Wu et al., 2007; Gabrea et al., 2008; 
Sawyer et al., 2014.). Sporadic cases with 
lymphoid malignancies: CLL in a 64-years old 
male (Juliusson et al 1985) and T-cell acute 
lymphocytic leukemia (ALL) in a 1 year old boy 






1 M/64 CLL 46,XY,add(9)(q34),del(11)(q22),+12,-13,-21,-22,+2mar/45,XY,+12,-21,-22/46,XY,t(1;8)(p12;q24) 
2 M/1 T-ALL 46,XY,t(1;8)(p13;q24),t(11;17)(q23;q25) 
3 M MM 
45-49,XY,t(1;8)(p11;q24),der(3)t(3;8)(p25;q?24),der(6)t(3;6)(q?21;q27),+der(7)t(7;?14)(q11;q11) 
t(1;14)(q11;q32),der(10)t(1;10)(q11;p15),-13,t(14;14)(q11;q32),+15,+18,+21 10-11.  
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5 ? MM 
59,X?,t(1;8)(p1?;q24),der(2)t(2;11)(q3;?),-4,-8,-10,-12,del(12)(p?),-13,-14, +15,-16,der(16)t(9;16) 
(q11;q11),-18,+19,-20  
6 M MM 
41-46,X,-Y,del(1)(p12p21),+i(1)(q10),t(1;8)(p12;q24),add(6)(q12),add(7)(p12),del(7)(p12),-8,add(12) 
(p13),del(12)(p11),-13,-14,+1-5mar  




1;?) (p11;?),+mar  
8 M MM 
53,X,-Y,+1,t(1;8)(p13;q24)x2,+3,+6,+7,+8,+9,+11,t(12;22)(q13;q12),-13,+15,i(17)(q10),del(20) 
(q11q12),+21 19-20.  










































Abbreviations: M, male; F, female; CLL, chronic lymphocytic leukemia; ALL, acute lymphoblastic 
leukemia/lymphoblastic lymphoma; MM, multiple myeloma.  
1. Juliusson et al., 1985; 2. Raimondi et al., 1993; 3-4. Sawyer et al., 1998; 5. Marzin et al., 2006; 6. Wu et al., 




The most common breakpoints described on 1p were 
1p13 (8 patients) and 1p11 (4 cases). 
Additional anomalies 
Found in a sideline in the CLL case (Juliusson et al., 
1985) and in association with t(11;17)(q23;q25) in a 
T-ALL (Raimondi et al., 1993); highly complex 
karyotypes in MM showing mainly either 
pseudodiploid, hypodiploid or near-
triploid/tertraploid karyotypes; associated with 
14q32 rearrangements in 6 (Sawyer et al., 1998; 
Gabrea et al., 2008; Sawyer et al., 2014) and 
del(13q)/-13 was found in 10 MM patients (Sawyer 
et al., 1998; Marzin et al., 2006; Wu et al., 2007; 
Gabrea et al., 2008; Sawyer et al., 2014). 
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The chromosomal translocation t(1;8)(p11-p13;q24) 
is found mainly in multiple myeloma, indicating that 
it may play an important role in myeloma 
pathogenesis or progression of disease. While the 
translocation involve the MYC loci at 8q24, its 
rearrangement and/or overexpression was studied 
only in a few reported patients (Gabrea et al., 2008). 
Translocations involving MYC have been shown to 
be important in B-cell maturation or myeloma 
pathogenesis resulting in its increased expression 
and an aggressive disease phenotype. MYC 
translocations in MM are often complex with non-
identified partner regions affecting non-IG partners 
(Walker et al., 2014). Therefore it is likely, that 
1p11-13 is an additional partner loci not involving an 
IG gene causing dysregulation of MYC affecting 
proliferation, growth and apoptosis. 
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